Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:LIPONASDAQ:NTBLNASDAQ:VLON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.19-14.7%$0.17$0.12▼$3.39$1.56M-0.051.01 million shs25,321 shsLIPOLipella Pharmaceuticals$2.56-5.6%$2.61$1.97▼$12.00$11.43M0.44722,899 shs21,329 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shsVLONVallon Pharmaceuticals$1.30-7.1%$0.67$0.21▼$12.92$17.53M-1.145.78 million shs113,343 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-14.73%-1.26%+4.28%+10.35%-91.19%LIPOLipella Pharmaceuticals-5.57%-14.41%+7.07%+19.02%-50.79%NTBLNotable Labs0.00%0.00%0.00%0.00%-71.53%VLONVallon Pharmaceuticals+6.06%-2.10%-6.04%-76.63%+457.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path2.0553 of 5 stars3.53.00.00.00.90.01.3LIPOLipella Pharmaceuticals2.2401 of 5 stars0.05.00.00.02.73.30.6NTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0010,560.98% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/ANTBLNotable Labs 2.00HoldN/AN/AVLONVallon Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ALIPOLipella Pharmaceuticals$536.36K21.31N/AN/A$4.33 per share0.59NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04VLONVallon Pharmaceuticals$100K175.27N/AN/A$0.18 per share7.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)LIPOLipella Pharmaceuticals-$4.62M-$4.08N/A∞N/A-882.82%-192.33%-154.24%N/ANTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/AVLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/ALatest BPTH, NTBL, LIPO, and VLON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86LIPOLipella PharmaceuticalsN/A2.972.97NTBLNotable Labs0.032.772.77VLONVallon PharmaceuticalsN/A2.292.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%LIPOLipella Pharmaceuticals74.31%NTBLNotable Labs70.48%VLONVallon Pharmaceuticals8.74%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%LIPOLipella Pharmaceuticals32.11%NTBLNotable Labs1.20%VLONVallon Pharmaceuticals37.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableLIPOLipella Pharmaceuticals44.47 million821,000Not OptionableNTBLNotable Labs409.02 million9.54 millionNo DataVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionableBPTH, NTBL, LIPO, and VLON HeadlinesRecent News About These CompaniesQuestcor Pharmaceuticals,July 21, 2023 | forbes.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 20, 2023 | bizjournals.comVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 12, 2023 | finance.yahoo.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 7, 2023 | bizjournals.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finanznachrichten.deVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finance.yahoo.comIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedFebruary 14, 2023 | benzinga.comVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventJanuary 11, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONDecember 27, 2022 | benzinga.comVallon rockets as it announces merger with GRI BioDecember 15, 2022 | thepharmaletter.comSay goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on NasdaqDecember 14, 2022 | endpts.comVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'December 14, 2022 | bizjournals.comWhat's Going On With Vallon Pharmaceuticals Stock Today?December 14, 2022 | msn.comWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving PremarketDecember 14, 2022 | benzinga.comVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsDecember 13, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJuly 28, 2022 | finance.yahoo.comVallon Pharmaceuticals, Inc. (VLON)July 20, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, NTBL, LIPO, and VLON Company DescriptionsBio-Path NASDAQ:BPTH$0.19 -0.03 (-14.73%) As of 06/13/2025 03:20 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Lipella Pharmaceuticals NASDAQ:LIPO$2.56 -0.15 (-5.57%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$2.56 +0.00 (+0.04%) As of 06/13/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.Vallon Pharmaceuticals NASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
